Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Completed 30Terminated 9Active not recruiting 8Recruiting 5Unknown 4Withdrawn 3

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5

Conditions

Multiple Myeloma 49Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Follicular 14Lymphoma, B-Cell, Marginal Zone 13Lymphoma 9Recurrence 7Lymphoma, Non-Hodgkin 7Neoplasms 6Lymphoma, Mantle-Cell 5Lymphoma, B-Cell 4Neoplasms, Plasma Cell 3Neoplasm, Residual 3Lymphoma, T-Cell, Peripheral 3Smoldering Multiple Myeloma 2Leukemia, Plasma Cell 2Hematologic Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Vitamin D Deficiency 1Peripheral Nervous System Diseases 1Paraproteinemias 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Diseases 1Heart Failure 1Dendritic Cell Sarcoma, Interdigitating 1Corneal Diseases 1Cardiotoxicity 1Blood Protein Disorders 1

Interventions

Rituximab 20zanubrutinib 13acalabrutinib 11Magnetic Resonance Spectroscopy 11obinutuzumab 10Specimen Handling 10Cyclophosphamide 10Biopsy 9glofitamab 8Bendamustine Hydrochloride 8pirtobrutinib 7fludarabine 7venetoclax 6orelabrutinib 6ibrutinib 5Lenalidomide 5Cytarabine 5fludarabine phosphate 3Immunotherapy, Adoptive 3CT-P10 3tafasitamab 2polatuzumab vedotin 2loncastuximab tesirine 2brexucabtagene autoleucel 2Whole-Body Irradiation 2Therapeutics 2Prednisone 2Melphalan 2Maintenance 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Mantle-Cell × Lenalidomide × Clear all
NCT07261163 2026-05-13

Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
37 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT03523975 2026-04-22

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

City of Hope Medical Center

Phase 1/2 Recruiting
28 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT07460362 2026-03-10

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

Peking University Third Hospital

Phase 2 Recruiting
43 enrolled
Lymphoid

Recurrence, Lymphoma, Mantle-Cell

NCT05861050 2026-02-19

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

City of Hope Medical Center

Phase 1/2 Recruiting
50 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT05910801 2024-11-18

V-MIND

Academic and Community Cancer Research United

Phase 2 Recruiting
100 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡